Finasteride and dutasteride are both irreversible 5-alpha-reductase inhibitors, but that describes their grip on one enzyme molecule, not a permanent change to your body. Three clocks explain the difference.
Finasteride and dutasteride, the two 5-alpha-reductase inhibitors used against hair loss, are both often called "irreversible." For a lot of people that single word does a lot of scary work: it sounds like something that happens to you and cannot be undone. The pharmacology is more specific than that, it is not identical for the two drugs, and the specifics matter.
The short answer: Both finasteride and dutasteride are technically irreversible (mechanism-based) inhibitors of 5-alpha-reductase, but "irreversible" describes only each drug's grip on a single enzyme molecule, not a permanent change to your body. Three different clocks get confused here. The drug clears from your blood on very different schedules: finasteride in hours (plasma half-life about 5 to 7 hours), dutasteride in weeks (plasma half-life about 5 weeks). A single drug-enzyme complex releases slowly, over about a month for finasteride and even slower for dutasteride. And your cells rebuild fresh enzyme continuously the whole time. "Irreversible" refers to that middle clock alone, for both drugs. Neither is a permanent change to the enzyme, and this is a separate question from whether symptoms can persist after stopping.
Yes, both are, in the precise biochemical sense. Finasteride and dutasteride are mechanism-based inhibitors, sometimes called "suicide" inhibitors, of the enzyme 5-alpha-reductase (Bull et al 1996, Rabasseda 2004). That is a real and specific category, different from a drug that simply drifts on and off its target.
But the word "irreversible" is doing something narrower than most people assume, and it means the same narrow thing for both drugs. It is a statement about the chemistry between one drug molecule and one enzyme molecule. It is not a statement that the enzyme is permanently destroyed in your tissues, and it is not a statement about you as a whole. To see why, and to see where the two drugs genuinely differ, it helps to separate three timescales that usually get blurred into one.
It means the enzyme builds its own trap. In an ordinary reversible inhibitor, the drug sits in the enzyme's pocket and can leave again. Finasteride and dutasteride are different: the enzyme starts to process the drug as if it were a normal substrate, and in doing so forms a covalent complex that behaves like a bisubstrate analog locked in place. For finasteride this was worked out in detail as the stable NADP-dihydrofinasteride complex, where the enzyme essentially catalyzes its own inhibition (Bull et al 1996). Dutasteride is in the same mechanism-based family and forms an even more slowly dissociating complex (Rabasseda 2004).
The key detail is what the covalent bond is between. It is between the drug and the enzyme's cofactor (NADP) inside the active site, forming a complex that dissociates extraordinarily slowly. It is not a permanent rewrite of your DNA or your hormones. It is one very tight, very long-lived molecular handshake.
For decades this complex was known only from its chemistry. Working from enzyme kinetics and mass spectrometry, Bull and colleagues deduced in 1996 that finasteride does not simply stick to the enzyme: the enzyme reduces the drug and fuses it to its own spent cofactor, forming a single combined molecule called NADP-dihydrofinasteride, a "bisubstrate analog" that occupies the space meant for the steroid and the cofactor at the same time (Bull et al 1996). In 2020 that inferred picture was finally seen directly, when the structure of human 5-alpha-reductase 2 with finasteride bound was solved and deposited (Xiao et al 2020). It confirmed the adduct: the drug sits in the active site with its key double bond reduced and covalently joined to the nicotinamide ring of NADP, essentially as predicted 24 years earlier.
There is a clean way to picture what the enzyme actually did. The very first thing 5-alpha-reductase does to finasteride is the same reaction it performs on testosterone: it reduces a double bond to make a "dihydro" product. The difference is the exit. When the substrate is testosterone, the product (DHT) is released and the enzyme moves on. When the substrate is finasteride, the "dihydro" product stays welded to the cofactor and never leaves. Finasteride is, in effect, a substrate that checks in and refuses to check out, and its extraordinary tightness comes from mimicking the transition state of the real reaction.
Dutasteride is understood to trap the enzyme by the same mechanism, and even more tightly, but it is worth being precise: the detailed complex that has actually been visualized is finasteride's. The dutasteride adduct is inferred from shared chemistry and kinetics, not confirmed by a solved structure of the same quality, so we describe it as very likely analogous rather than directly demonstrated. How long that trap lasts, and how it eventually resolves, is where the three clocks come in, and where the two drugs finally diverge.
This is where they differ most. Finasteride's plasma half-life is only about 5 to 7 hours (Steiner 1996), so within roughly a day of your last dose the free drug is largely cleared from circulation. Dutasteride is the opposite extreme: its plasma half-life is about 5 weeks (Clark 2004), so it genuinely lingers in the body for months after the last dose.
That single difference explains a lot of the folklore. Finasteride being "irreversible" while gone from blood by tomorrow sounds like a contradiction, until you separate the drug leaving your blood from the drug releasing its grip on an enzyme molecule. And dutasteride "taking forever to leave" is simply true at the level of the drug itself: it is a genuinely long-lived molecule in the body, on Clock 1, before you even get to the enzyme.
About a month for a single finasteride complex, and longer still for dutasteride. Once finasteride has formed its covalent NADP-dihydrofinasteride complex with the type 2 enzyme, it lets go only very slowly, on the order of roughly a month (Bull et al 1996). Dutasteride forms an even tighter, more slowly dissociating complex, and unlike finasteride it does this on both isoforms: dutasteride blocks type 1 and type 2, while finasteride is largely selective for type 2 (Rabasseda 2004). This is the clock that earns both drugs the label "irreversible."
It is also the number that gets misquoted the most. People sometimes describe finasteride as having a long "tissue half-life" or a month-long "scalp half-life." That is a misreading: the roughly one-month figure is the dissociation of the enzyme-inhibitor complex measured in the lab, not a measurement of how long the drug lingers in scalp tissue. No scalp or tissue half-life has actually been measured for either finasteride or dutasteride. When you see a long "tissue half-life" quoted, it is almost always this complex-dissociation number wearing the wrong label. (Dutasteride does linger a long time, but that is Clock 1, its real plasma half-life, not a scalp measurement.)
Continuously, and this is identical for both drugs. This is the clock that most "irreversible" discussions leave out entirely, and it is the one that changes the whole picture. 5-alpha-reductase is a protein, and proteins are not permanent fixtures. Cells are constantly making new enzyme and breaking down old enzyme as part of normal turnover.
Neither finasteride nor dutasteride switches off the gene or stops the cell from manufacturing new enzyme; each only blocks the activity of the enzyme molecules it binds. So even while some enzyme molecules are locked up in that slowly-releasing complex, fresh, un-blocked enzyme keeps being produced. The total activity you have at any moment is a balance between molecules being trapped and new molecules arriving. That is why both drugs have to be taken continuously to keep working: neither is a one-time permanent switch, each is an ongoing competition with your own resupply.
So which clock actually wins, the enzyme's slow release (Clock 2) or the cell's recycling (Clock 3)? Almost certainly the recycling. Most proteins turn over on the order of hours to a few days, far faster than the roughly one-month dissociation of the drug-enzyme complex, so a jammed enzyme molecule is very likely degraded and rebuilt, with the drug still attached, long before that drug would have let go on its own. We say almost certainly because a clean in-vivo human turnover rate for 5-alpha-reductase itself has not been well measured; this is reasoning from typical protein turnover, not a pinned-down 5-alpha-reductase number. The practical consequence is the part that matters: what paces your recovery after stopping is not the slow complex release but how long the drug lingers in your body (Clock 1). As long as any drug remains, it simply re-binds the fresh enzyme the cell keeps making. That is why finasteride, cleared from blood in hours, recovers over weeks, while dutasteride, with its roughly five-week plasma half-life, keeps re-jamming newly made enzyme and recovers over months.
On the biology of the enzyme, yes for both, just on different timescales. Put the three clocks together. When you stop, no new drug arrives, the already-bound complexes release over the following weeks to months, and your cells keep producing new, un-blocked enzyme the entire time. The result is that 5-alpha-reductase activity, and therefore DHT production, returns.
The difference between the two drugs is speed, not permanence. Finasteride reverses relatively quickly, on the order of weeks, because it clears blood in hours and holds the enzyme for about a month. Dutasteride reverses more slowly, on the order of months, for two honest reasons: it washes out of the body far more slowly (Clock 1, the ~5 week plasma half-life) and it grips the enzyme more tightly and on both isoforms (Clock 2). That combination is also why dutasteride suppresses DHT more completely in the first place: it drove serum DHT down by more than 90% in men with benign prostatic hyperplasia (Clark 2004), and in a hair-loss context dual inhibition lowered scalp and serum DHT more than type-2-selective inhibition (Olsen 2006). Slower to reverse is not the same as permanent.
This is where honesty matters most. The three-clock argument is about enzyme kinetics: how long each drug lasts, how long it grips the enzyme, and how fast the enzyme is replaced. It explains why "irreversible inhibitor" does not mean "permanent change to you," and why DHT suppression is expected to reverse after stopping either drug.
It does not, by itself, settle whether a small number of people experience persistent symptoms after discontinuing finasteride or dutasteride, sometimes discussed under the label post-finasteride syndrome. That is a separate and genuinely unresolved question, and it is being investigated on its own terms. The binding numbers in this article do not prove such symptoms are impossible, and they do not prove they are common. Anyone telling you the kinetics alone close that debate, in either direction, is overreaching. We are describing the enzyme chemistry, not adjudicating that clinical question. Both drugs are prescription decisions with their own benefit and risk profiles that belong with a clinician.
Neither is permanent. Finasteride's plasma half-life is about 5 to 7 hours (Steiner 1996) and dutasteride's is about 5 weeks (Clark 2004), and although each drug-enzyme complex takes time to release (Bull 1996), your cells continuously make new, un-blocked enzyme. That is why both drugs must be taken continuously, and why DHT suppression reverses after stopping.
A mechanism-based (suicide) inhibitor is one the target enzyme activates against itself. With finasteride, 5-alpha-reductase begins processing the drug and forms a stable covalent NADP-dihydrofinasteride complex that locks the enzyme molecule up (Bull 1996). Dutasteride works the same way and grips even more tightly (Rabasseda 2004). It is different from a reversible inhibitor, which can simply drift off.
No scalp or tissue half-life has ever been measured for either drug. The month-long figure people quote for finasteride is the dissociation time of the enzyme-inhibitor complex measured in the lab (Bull 1996), not tissue lingering. Dutasteride does stay in the body for months, but that is its plasma half-life of about 5 weeks (Clark 2004), not a scalp measurement.
Finasteride itself clears from blood within about a day given its 5 to 7 hour half-life (Steiner 1996), and enzyme activity recovers over roughly the following month. Dutasteride takes much longer because its plasma half-life is about 5 weeks (Clark 2004), so its effect fades over months. Both reverse; dutasteride is just slower.
Dutasteride grips the enzyme even more tightly and blocks both isoforms, while finasteride is largely type-2-selective (Rabasseda 2004). The bigger difference is that dutasteride's plasma half-life is about 5 weeks versus finasteride's few hours (Clark 2004), so it lingers longer and its DHT suppression reverses over months, not weeks. That is slow washout, not a permanent change.
The irreversible label refers to enzyme kinetics, not to persistent symptoms. The binding numbers explain why DHT suppression reverses after stopping either finasteride or dutasteride; they do not prove or disprove that some people experience lasting symptoms, which is a separate, unresolved question under active investigation. Anyone claiming the kinetics settle that debate is overreaching.
This article is educational and is not medical advice. It describes the enzyme kinetics of 5-alpha-reductase inhibitors, not the diagnosis or treatment of any condition, and it makes no claim about the efficacy or safety of any medication. Finasteride 1 mg is FDA-approved for male androgenetic alopecia; dutasteride is used off-label for hair loss in the United States. Talk to a qualified clinician about your own care.